How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

62. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

extensively drug-resistant tuberculosis XTC 3TC or FTC WHO World Health Organization VMMC voluntary medical male circumcision 3TC lamivudine ABC abacavir ATV atazanavir AZT zidovudine COBI cobicistat d4T stavudine ddI didanosine DRV darunavir DTG dolutegravir EFV efavirenz ETV etravirine EVG elvitegravir FTC emtricitabine FPV fosamprenavir IDV indinavir LPV/r lopinavir/ritonavir NVP nevirapine RAL raltegravir RIL rilpivirine RTV ritonavir SQV saquinavir TAF tenofovir alafenamide fumarate TPV tipranavir

2016 World Health Organisation HIV Guidelines

63. Tivicay - dolutegravir

transcriptase inhibitor OBR Optimized background regimen OSS Overall susceptibility score PDVF Protocol defined virologic failure PI Protease inhibitor PIQ Phenotypic inhibitory quotient PK/PD Pharmacokinetic/pharmacodynamic PSS Phenotypic susceptibility score Assessment report EMA/CHMP/772068/2013 Page 4/102 RAL raltegravir RAM Resistance associated mutation RNA Ribonucleic acid RTV ritonavir TLOVR Time to Loss of Virologic Response TDF tenofovir disoproxil fumarate TPV tipranavir UNAIDS Joint United

2014 European Medicines Agency - EPARs

64. Rezolsta - darunavir / cobicistat

additivity with all nucleoside/nucleotide reverse transcriptase inhibitors, all tested non-nucleoside reverse transcriptase inhibitors. A modest synergistic effect with amprenavir, nelfinavir and ritonavir was observed whereas additive effects were described for the combination with atazanavir, indinavir, lopinavir, saquinavir, and tipranavir and with the fusion inhibitor enfuvirtide. Cobicistat Cobicistat is a structurally modified analogue of the protease inhibitor ritonavir, which is devoid of anti

2014 European Medicines Agency - EPARs

67. Vitekta - elvitegravir

EVG/r and tipranavir (TPV/r) GS-US-183-0123 multiple-dose DDI EVG/r and fosamprenavir (FPV)/r GS-US-183-0120 multiple-dose DDI EVG/r and darunavir (DRV)/r GS-US-183-0147 multiple-dose DDI EVG and ATV GS-US-183-0106 and -0108 effect of ATV/r on boosted EVG EVG and COBI GS-US-201-0104 evaluated the PK of EVG and COBI when co- administered with DRV GS-US-216-0116 EVG administered with 2 formulations of COBI GS-US-216-0123 evaluated unboosted ATV, rosuvastatin and dose-reduced rifabutin on EVG

2013 European Medicines Agency - EPARs

68. Tybost - cobicistat

-tablet regimen TDF tenofovir disoproxil fumarate (Viread ? ) TFV tenofovir TLOVR time to loss of virologic response TPV tipranavir TVD emtricitabine/tenofovir disoproxil fumarate, coformulated (Truvada ? ) UGT uridine diphosphate glucuronosyltransferase ULN upper limit of the normal range ZDV zidovudine Assessment report Page 6/86 1. Background information on the procedure 1.1. Submission of the dossier The applicant Gilead Sciences International Ltd submitted on 26 April 2012 an application

2013 European Medicines Agency - EPARs

69. Stribild - elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil

-associated mutation TDF tenofovir disoproxil fumarate (Viread ® ) TFV tenofovir TLOVR time to loss of virologic response TPV tipranavir TSH thyroid-stimulating hormone TVD emtricitabine/tenofovir disoproxil fumarate, coformulated (Truvada ® ) UGT uridine glucuronosyltransferase ULN upper limit of the normal range US/USA United States/United States of America VLDL very low-density lipoprotein WBC white blood cell ZDV zidovudine AUC area under the plasma concentration-time curve AUC 0-last area under

2013 European Medicines Agency - EPARs

70. Dyspepsia - pregnancy-associated

. Tipranavir — the plasma concentration of omeprazole is reduced. Atazanavir — proton pump inhibitors decrease plasma levels. Itraconazole and ketoconazole — proton pump inhibitors decrease absorption of these drugs. Methotrexate — excretion of methotrexate may be reduced with concurrent use of proton pump inhibitors, leading to increased levels and increased risk of toxicity. Inducers of CYP2C19 and CYP3A4 (for example rifampicin and St John's wort) — omeprazole metabolism may be increased by these drugs

2017 NICE Clinical Knowledge Summaries

71. Dyspepsia - proven GORD

efficacy. If concurrent use is necessary, seek specialist advice. Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects. Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice. [ ; ] H2-receptor antagonists H2-receptor antagonists Choice of H2-receptor antagonist Choice of H2-receptor

2017 NICE Clinical Knowledge Summaries

74. Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease Full Text available with Trip Pro

Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease Four HIV-1 protease (PR) inhibitors, clinical inhibitors lopinavir and tipranavir, and two investigational compounds 4 and 5, were studied for their effect on the structure and activity of PR with drug-resistant mutation L76V (PRL76V). Compound 5 exhibited the best Ki value of 1.9 nM for PRL76V, whereas the other three inhibitors had Ki values of 4.5-7.6 nM, 2-3 orders of magnitude worse

2018 ACS Omega

75. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. Full Text available with Trip Pro

, indinavir/r, saquinavir/r, fosamprenavir/r, and tipranavir/r should be included. The expert panel members provided highly concordant DRM pattern-ARV interpretations with only 6% of NRTI, 6% of NNRTI, 5% of PI, and 3% of INSTI individual expert interpretations differing from the expert panel median by more than one resistance level. The expert panel median differed from the HIVDB 7.0 GRT-IS for 20 (12.5%) of the 160 DRM pattern-ARV combinations including 12 NRTI, two NNRTI, and six INSTI pattern-ARV

2017 PLoS ONE

76. Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients

, carbamazepine, St. John's Wort, efavirenz, neivrapine, etravirine, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, cobicistat Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03713645 Contacts Layout

2018 Clinical Trials

77. Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African Am

) Efavirenz (EFV) Nevirapine (NVP) Rilpivirine (RPV) Integrase inhibitors Dolutegravir (DTG) Elvitegravir (EVG) Raltegravir (RAL) Protease inhibitors (PIs) Atazanavir (ATV) Darunavir (DRV) Lopinavir Nelfinavir NFV) Saquinavir (SQV) Tipranavir (TPV) Third agents will be administered as prescribed without regard to food. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. Outcome Measures Go to Primary Outcome Measures : Proportion

2018 Clinical Trials

78. Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

, saquinavir, or tipranavir; Corticosteroids, either systemically, inhaled, intranasally, orally, or by intra-articular injection within 14 days before the study surgical procedure (topical corticosteroid is allowed); Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to the study surgical procedure; Any investigational product within 30 days prior to administration of blinded study medication. History of alcohol abuse or prescription and/or illicit drug abuse within 2 years prior

2018 Clinical Trials

79. 2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Full Text available with Trip Pro

and the addition of maraviroc, tipranavir and elvitegravir to the system.The no-genotype models achieved area under the receiver operator characteristic curve (AUC) values of 0.82 and 0.81 using the standard and relaxed baseline data windows, respectively. The genotype models achieved AUC values of 0.86 with the new non-adherence filter and 0.84 without. Both sets of models were significantly more accurate than genotyping with rules-based interpretation, which achieved AUC values of only 0.55-0.63, and were

2018 Journal of Antimicrobial Chemotherapy

80. Hepatitis C (HCV) Cure and Kidney Health

/grazoprevir Co-administration with drugs that are 1) strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin); 2) OATP1B1/3 inhibitors (e.g., cyclosporine, darunavir, atazanavir, tipranavir, lopinavir or saquinavir) or 3) efavirenz Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>